olaparib plus abiraterone for mcrpc: are biomarkers necessary?
Published 6 years ago • 127 plays • Length 1:37Download video MP4
Download video MP3
Similar videos
-
1:45
the propel clinical trial exploring olaparib plus abiraterone in mcrpc
-
3:07
propel: olaparib plus abiraterone as 1l treatment for metastatic crpc
-
3:41
olaparib plus abiraterone could be a new first-line treatment option for mcrpc | fred saad
-
0:44
propel: gene-by-gene efficacy of olaparib and abiraterone in mcrpc
-
0:51
propel: analysis of drug interactions between olaparib abiraterone as 1l therapy in mcrpc
-
9:59
profound performance: olaparib vs. enzalutamide or abiraterone for hrr altered mcrpc
-
1:40
dr. maughan discusses abiraterone plus olaparib in mcrpc
-
4:08
propel: final os of first-line abiraterone plus olaparib for mcrpc
-
4:56
fred saad, esmo 2022: phase iii propel trial of abiraterone olaparib in prostate cancer
-
2:45
biomarker analysis and updated results from propel
-
8:53
prognostic biomarkers to guide treatment of mcrpc
-
1:15
magnitude: hrqol in patients with mcrpc receiving niraparib and abiraterone
-
1:06
the benefits of 177lu-psma-617 plus olaparib for prostate cancer
-
1:27
hrqol and pain outcomes in mcrpc: abi ala vs abi pbo in propel
-
4:55
18f-fluciclovine pet in mcrpc treated with abiraterone acetate
-
4:21
phase ii results of olaparib and abiraterone for mcrpc
-
5:40
parp inhibitors in advanced prostate cancers
-
4:30
profound: olaparib for hrr mcrpc
-
3:47
parp inhibitors for metastatic hormone sensitive prostate cancer